International report: Syneron cancels its investor rights plan.

Syneron Medical (Yokneam, Israel), an aesthetic gadget company, said its board has actually terminated the investor rights plan. The investor rights plan was adopted on Nov. 11, 2008 after a decline available price of Syneron's typical stock to make certain that all Syneron investors would certainly be handled fairly in case of any type of unrequested requisition of the firm. Offered the business's preserved development, economic toughness and the dissatisfaction of its shareholders to the continuation of the shareholder civil liberties plan, Syneron's board of supervisors determined that the security offered by the investor rights strategy is not warranted.

"The board takes satisfaction in properly serving the best passions of Syneron's shareholders, as well as its dedication to sturdy corporate administration policies and practices," claimed Shimon Eckhouse, chairman of the board. We brought that message back to the board and reconsidered the need for the investor civil liberties strategy. Here are some more findings on Invisible braces Melbourne .

The amendment to the shareholder rights plan will be filed with the Securities and Exchange Commission on a Form 6-K.

Syneron says its technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela.

Dehaier to equip Hospital 301 in Beijing
Dehaier Medical Systems (Beijing, China), a maker of medical devices and homecare medical products in China, has signed a medical equipment supply agreement with Hospital 301 (also Beijing). The contract is valued at $1.32 million, and Dehaier expects to recognize all revenues from the contract in 2011.
Under the agreement Dehaier will provide the Hospital 301 with a Small Animal In-vivo Imaging System and two sets Laser Capture Microdissection Systems (LCM), both of which are manufactured by Leica, and DNA sequencers manufactured by ABI.

"Hospital 301 is one of the largest and most well renowned hospitals in China and we are honored to provide devices to the hospital. We are also pleased to have the chance to work with two well-respected medical device manufacturers such as Leica and ABI. This supply agreement demonstrates our ability to continue to make inroads with leading hospitals throughout the country and key international medical device manufacturers," said Ping Chen, CEO of Dehaier. "In over ten years of distributing medical devices in China, we have built strong relationships with over 3,000 hospitals and 2,000 dealers and distributors nationwide. Along with the solid development of medical devices business, we believe that this large, diversified growing network provides us with an ideal platform on which to expand and accelerate the growth of our homecare business."

Dehaier's product line includes respiratory and oxygen homecare medical products.
Align readies Invisalign for Chinese distribution

Align Technology (San Jose, California) said the Invisalign system is now commercially available in China. The company is training orthodontists based in the four major cities of Shanghai, Beijing, Shenzhen, and Guangzhou, which have a combined population of more than 70 million people. Align is offering Invisalign Full, Invisalign Teen and Vivera Retainers directly to Invisalign-trained orthodontists.

China is estimated to have nearly half a million new orthodontic case starts each year, with a higher percentage of complex Class II and III malocclusion cases than in Western countries. In October 2010, Align received regulatory approval from the Chinese State Food and Drug Administration (SFDA) to market and sell the Invisalign system as a Class II medical device for the treatment of malocclusion. In conjunction with the recent international launch of Invisalign G3, Align accelerated commercial availability of Invisalign in China from the second half of 2011. The new features and functionality delivered with Invisalign G3 are engineered to make Invisalign easier to use with Class II and III patients and address the higher complexity of malocclusion among the Asian population. In anticipation of this launch Align has been building its presence in China and has established its office in Shanghai which includes country management, sales, marketing, clinical education, and support.

Align Technology makes Invisalign, a method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position.